Holen Sie sich die Stockscreener-App
15.95
0.25%
-0.04
Handel nachbörslich:
15.95
Schlusskurs vom Vortag:
$15.99
Offen:
$16.01
24-Stunden-Volumen:
1.88M
Relative Volume:
1.33
Marktkapitalisierung:
$1.86B
Einnahmen:
$674.41M
Nettoeinkommen (Verlust:
$-173.05M
KGV:
-10.40
EPS:
-1.5343
Netto-Cashflow:
$-48.07M
1W Leistung:
-1.85%
1M Leistung:
-9.63%
6M Leistung:
+46.33%
1J Leistung:
+23.45%
1-Tages-Spanne:
$15.73
$16.09
1-Wochen-Bereich:
$15.20
$16.43
52-Wochen-Spanne:
$9.82
$21.45
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
15.95 | 1.84B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
NovoCure stock reports 15.6 percent Q2 revenue growth - AD HOC NEWS
NovoCure Limited (NVCR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is NovoCure (NVCR) Undervalued On TTFields Validation And Board Change? - simplywall.st
NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall - Yahoo Finance Singapore
NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change - Yahoo Finance Singapore
Growth Plan Might Change The Case For Investing In NovoCure Stock (NVCR) - simplywall.st
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even - TradingView
Is It Too Late to Buy NovoCure Ltd (NVCR) After 3.1% Rally? GF V - GuruFocus
Novocure at Morgan Stanley conference: growth, discipline and expansion By Investing.com - Investing.com India
NovoCure Limited at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
NovoCure (NVCR) Stock Looks Cheap On Sales But Weak On Adoption Risk - simplywall.st
NovoCure (NASDAQ: NVCR) Announces Board Vacancy Following Timothy Scannell's Departure on September 2, 2026 - kalkinemedia.com
NovoCure at Wells Fargo healthcare conference: launch momentum builds By Investing.com - Investing.com South Africa
NovoCure at Wells Fargo healthcare conference: launch momentum builds - Investing.com
Novocure Ltd Announces Retirement of Timothy Scannell from the Board, Effective September 2, 2026 - marketscreener.com
Timothy Scannell retires from NovoCure board, seat vacated Sept 2, 2026 - TradingView
NovoCure (NASDAQ: NVCR) director steps down with no dispute - Stock Titan
Novocure Reports Patient Data Exposure in Cybersecurity Incident - Yahoo Finance
Novocure Stock Price Forecast. Should You Buy NVCR? - StockInvest.us
NOVOCURE LTD (NVCR) Stock Chart - ChartMill
Novocure Ltd (NVCR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cash flow from operating activities of NovoCure Ltd. – HAM:038 - TradingView
Net debt of NovoCure Ltd. – HAM:038 - TradingView
NovoCure says cyberattack caused patient data exposure - Yahoo Finance
Basic earnings per share (basic EPS) of NovoCure Ltd. – HAM:038 - TradingView
NovoCure (NVCR) Stock May Be Cheap Based On Sales Growth Risk - simplywall.st
NewsNovocure discloses cyberattack exposing records of more than 1,400 US cancer patients - teiss
Novocure Announces Upcoming Investor Events - finance.yahoo.com
NovoCure (NASDAQ: NVCR) Data Breach Exposes IDs Linked to Over 1,400 U.S. Patient Records - Kalkine Media
Novocure Reveals Major Breach of Cancer Patient Records - sqmagazine.co.uk
Oncology firm Novocure says cyberattack exposed US patient records - CNA
NVCR Looks 3.4% Undervalued on GF Value™ Amid Cybersecurity Inci - GuruFocus
Novocure reports data access affecting patient IDs for 1,400+ U.S. records; no device access - TradingView
NovoCure cyber breach hits 1,400+ patient records - Stock Titan
Novocure Ltd (NVCR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Novocure Ltd (NVCR) Peer Comparison – Compare with Others - Value Research
Is NovoCure (NVCR) A Bargain On Rising Earnings Estimates? - simplywall.st
NovoCure Limited (NVCR) Stock Price & News - Syfe
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Yahoo Finance
Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors? - simplywall.st
A Look at NovoCure Ltd (NVCR) After 3.7% Decline -- GF Value $18 - GuruFocus
NovoCure (NASDAQ:NVCR) Shares Down 4%What's Next? - MarketBeat
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice - Yahoo Finance
Novocure | 8-K: Current report - Moomoo
What’s Behind NovoCure (NVCR) Shares Climbing Today? - simplywall.st
NVCR|Novocure Ltd|Price:18.200|Chg%:+0.960 - TradingKey
NVCR Q2 2026 Earnings: Loss Narrower Than Expected; Shares Slip 0.82Earnings Preview - vinanet.vn
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet - Yahoo Finance
NovoCure (NVCR) Is Up 8.5% After Advancing Tumor Treating Fields Pipeline And Trials ProgressHas The Bull Case Changed? - simplywall.st
First Trust Advisors LP Invests $1.03 Million in NovoCure Limited $NVCR - marketbeat.com
NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued - simplywall.st
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Novocure Ltd-Aktie (NVCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leonard Frank X | Chief Executive Officer |
Jun 04 '26 |
Sale |
17.93 |
34,273 |
614,635 |
459,520 |
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):